Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Discovery Grants Program - Individual

University of Manitoba

$45,000.00

Novel functions of C1q/TNF-related relaxin receptor ligands

EF 2023-24

Résumé
My NSERC-DG program had discovered C1q/TNF-related protein 8 (CTRP8) as a new ligand of relaxin receptor RXFP1 and uncovered new signaling cascades with functional impact on cell motility and genome integrity. My lab has introduced the first highly specific CTRP8 antiserum as a versatile immunodetection tool, enabling the pioneering discovery of innate immune functions in CTRP8 biology. Using a yeast-based protein interaction assay, I identified several CTRP8 interaction partners with intriguing biologies. Membrane-anchored stem cell factor DLK1, a non-classical ligand of NOTCH receptor, had the highest interaction score of all putative CTRP8 interaction partners. We confirmed the DLK1-CTRP8 interaction using antibody-based techniques, which included the use of our new CTRP8 antiserum. We identified a critical role of the DLK1 extracellular EGF-like domains 1-5 for the interaction with CTRP8. Like activated NOTCH receptor, DLK1 employs an enzymatically cleaved intracellular domain (ICD) that shuttles to the nucleus to initiate nuclear DLK1-ICD signaling, likely by contributing to the formation of transcriptional complexes at specific genomic sites. I discovered that the CTRP8 interaction with membrane-bound DLK1 increased nuclear DLK1-ICD and this coincided with altered stem cell marker expression. By using both RXFP1 and DLK1 receptor systems, CTRP8, and likely also CTRP1, trigger distinct signaling mechanisms. Hypoxic stress strongly upregulates DLK1, but not RXFP1, and suggests dynamic CTRP1/8 receptor utilization with impact on (stem) cell differentiation depending on tissue oxygenation levels. The long-term goal of my NSERC-DG program is to create a comprehensive profile of CTRP functions that are facilitated by RXFP1 and DL K1 receptors. This centers around discoveries of new biological mechanisms eliciting specific measurable cell and tissue responses. My first two short-term objectives (SO) investigate fundamental structure-function requirements of the new CTRP8-DLK1 interaction and explore the impact of hypoxia on signaling via the two CTRP8 receptors in different cell models. The third SO builds on my recent discoveries that innate immune cells can be both a source and target of CTRP8 and the exciting finding in mouse brain xenograft models that glial cells co-expressing CTRP8 and RXFP1, but not those co-expressing CTRP8 and DLK1, show rapid growth. SO#3 proposes new mouse models, including the first humanized CTRP8-RXFP1 transgenic mouse model, to study the paracrine effects of CTRP8 secreted by microglia on RXFP1+ glial cells and on the brain microenvironment. As a world leader in CTRP8 research, our discoveries linking CTRP8 with NOTCH signaling and innate immunity will provide unique opportunities for HQP to contribute to this cutting-edge science.
Programme
Discovery Grants Program - Individual
Emplacement
Manitoba, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data

Tel que publié

Application id
RGPIN-2023-04286
Name nom
Klonisch, Thomas
Department département
Human Anatomy and Cell Science
Organization id
19
Institution établissement
University of Manitoba
Province en
Manitoba
Province fr
Manitoba
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2023
Competition year année de concours
2023
Award amount
45000
Program id
RGPIN
Program name en
Discovery Grants Program - Individual
Program name fr
Programme de subventions à la découverte - individuelles
Group en
DISCOVERY RESEARCH
Group fr
RECHERCHE AXÉE SUR LA DÉCOUVERTE
Committee code
1501
Committee name en
Genes, Cells and Molecules
Committee name fr
Gènes, cellules et molécules
Area of application code
1211
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Medical and health sciences
Area of application fr
Sciences médicales et de la santé
Research subject code
9000
Research subject group en
Medical sciences
Research subject group fr
Medical sciences
Research subject en
Sciences médicales
Research subject fr
Sciences médicales
Application title
Novel functions of C1q/TNF-related relaxin receptor ligands
Keyword
autophagy; C1q/TNF-related proteins; CTRP; glial cells; macrophages; mast cells; NOTCH1; Pref-1; relaxin receptor; RXFP1
Application summary
My NSERC-DG program had discovered C1q/TNF-related protein 8 (CTRP8) as a new ligand of relaxin receptor RXFP1 and uncovered new signaling cascades with functional impact on cell motility and genome integrity. My lab has introduced the first highly specific CTRP8 antiserum as a versatile immunodetection tool, enabling the pioneering discovery of innate immune functions in CTRP8 biology. Using a yeast-based protein interaction assay, I identified several CTRP8 interaction partners with intriguing biologies. Membrane-anchored stem cell factor DLK1, a non-classical ligand of NOTCH receptor, had the highest interaction score of all putative CTRP8 interaction partners. We confirmed the DLK1-CTRP8 interaction using antibody-based techniques, which included the use of our new CTRP8 antiserum. We identified a critical role of the DLK1 extracellular EGF-like domains 1-5 for the interaction with CTRP8. Like activated NOTCH receptor, DLK1 employs an enzymatically cleaved intracellular domain (ICD) that shuttles to the nucleus to initiate nuclear DLK1-ICD signaling, likely by contributing to the formation of transcriptional complexes at specific genomic sites. I discovered that the CTRP8 interaction with membrane-bound DLK1 increased nuclear DLK1-ICD and this coincided with altered stem cell marker expression. By using both RXFP1 and DLK1 receptor systems, CTRP8, and likely also CTRP1, trigger distinct signaling mechanisms. Hypoxic stress strongly upregulates DLK1, but not RXFP1, and suggests dynamic CTRP1/8 receptor utilization with impact on (stem) cell differentiation depending on tissue oxygenation levels. The long-term goal of my NSERC-DG program is to create a comprehensive profile of CTRP functions that are facilitated by RXFP1 and DL K1 receptors. This centers around discoveries of new biological mechanisms eliciting specific measurable cell and tissue responses. My first two short-term objectives (SO) investigate fundamental structure-function requirements of the new CTRP8-DLK1 interaction and explore the impact of hypoxia on signaling via the two CTRP8 receptors in different cell models. The third SO builds on my recent discoveries that innate immune cells can be both a source and target of CTRP8 and the exciting finding in mouse brain xenograft models that glial cells co-expressing CTRP8 and RXFP1, but not those co-expressing CTRP8 and DLK1, show rapid growth. SO#3 proposes new mouse models, including the first humanized CTRP8-RXFP1 transgenic mouse model, to study the paracrine effects of CTRP8 secreted by microglia on RXFP1+ glial cells and on the brain microenvironment. As a world leader in CTRP8 research, our discoveries linking CTRP8 with NOTCH signaling and innate immunity will provide unique opportunities for HQP to contribute to this cutting-edge science.